Petra Kaufmann
Executive Officer at Affinia Therapeutics
Bethesda, Maryland, United States
Find your path to Petra
241 people in our graph can introduce you to Petra.
Sign up to see every warm intro you have to Petra
- Paths you didn't know you had: your email and LinkedIn already hold routes to Petra. We find them
- 2nd- and 3rd-degree connections: the friend-of-a-friend routes you can't see from your own inbox or LinkedIn
- Answers now, not in days: momentum is everything in a raise. Skip asking around whether someone knows someone
Days of research, done the moment you sign in, with every route ranked by how warm it is.
Experience
- Ovid TherapeuticsChief Medical Officercurrent2025 — presentNew York, NY
- Vigil NeuroscienceChief Medical Officer2024 — 2025Cambridge, Massachusetts, United States
- Affinia TherapeuticsChief Medical Officer2021 — 2024
- Novartis Gene TherapiesSenior Vice President, Clinical Development, Analytics & Translational Medicine2020 — 2021Bethesda, Maryland, United States
- AveXis, Inc.Vice President, R&D Translational Medicine2018 — 2020
- The National Institutes of Health/National Center for Advancing Translational SciencesDirector, Office of Rare Diseases Research2015 — 2018
- The National Institutes of HealthDirector, Division of Clinical Innovation2014 — 2017
- National Institute of Neurological Disorders and Stroke (NINDS)Director, Office of Clinical Research2009 — 2014
- Columbia University Irving Medical CenterNeurology Faculty (with tenure)2000 — 2009
Skills & more
ManagementLeadershipStrategic PlanningResearch AdministrationNeurology
Languages English · French · German
- Preparing to be a Corporate Director — Harvard Business School Executive Education
From Petra's professional profile.
Frequently asked questions
- Who is Petra Kaufmann?
- Executive Officer at Affinia Therapeutics
- Where did Petra Kaufmann go to school?
- Petra Kaufmann studied at Columbia University (Master of Science, Biostatistics/Patient-oriented Research); Columbia University (Neurology Residency Program); Columbia University (Post-doctoral Fellowship, Mitochondrial diseases, molecular genetics).
Same school
Also attended Columbia University1,434
Ben HorowitzCo-founder & General Partner at Andreessen HorowitzDoug LeonePartner at Sequoia Capital; former Global Managing PartnerChris DixonFounder & Managing Partner of a16z crypto at Andreessen HorowitzKai-Fu LeeChairman of Sinovation Ventures and CEO of 01.AIGabriella GiglioHR & Executive Talent at General CatalystScott BillerInvestor at GV (Google Ventures)
+ 1,428 more
Also attended The University of Bonn59
Miriam UeberallTuring Labs AI; Ex-R&D at Flora Food Group, Kraft Heinz, Unilever at PeakBridge VCJörg BinnenbrückerManaging Partner at CapnamicStella PaffenholzSenior Associate at Atlas VentureLennart SchlegelManager Investor Relations at FoodLabsChristophe WagnerInterim CFO at FoodLabsPetra KurschatTeam Manager at Seed+Speed
+ 53 more
Shared employers
Also worked at Ovid Therapeutics8
Rachel LanePrincipal at Versant VenturesMeg AlexanderPresident & Chief Executive Officer at OvidrxCharles CarterChief Financial Officer at OvidrxVictoria FortChief Strategy Officer at OvidrxManal MorsyChief Regulatory Officer at OvidrxKevin NorrettChief Business Officer at Ovidrx
+ 2 more
Also worked at Novartis Gene Therapies349
Rebecca JamesInvestor at Index VenturesScott BillerInvestor at GV (Google Ventures)Freya Svedberg-KeatingInvestor at MedicxiAndrea AmadorCompliance Manager at Inveready Technology Investment GroupAbbie CelnikerInvestor at Third Rock VenturesJesper GromadaInvestor at Third Rock Ventures
+ 343 more
Also worked at AveXis, Inc.3
Also worked at The National Institutes of Health/National Center for Advancing Translational Sciences129
Jun JeonInvestor at Khosla VenturesUri LopatinInvestor at Khosla VenturesMax ColbertPhysician-Entrepreneur at Medical Excellence CapitalAnnie VemuSenior Associate at Longwood FundVictoria GraceFounding partner of Colle Capital Partners, an opportunistic early-stage technology venture fundAshok SrinivasanChief Science Advisor at AIF
+ 123 more



































